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The mechanistic target of rapamycin complex 1 (mTORC1) has received much attention in the field of exercise physiology
as a master regulator of skeletal muscle hypertrophy. The multiprotein complex is regulated by various signals such as
growth factors, energy status, amino acids and mechanical stimuli. Importantly, the glycerophospholipid phosphatidic
acid (PA) appears to play an important role in mTORC1 activation by mechanical stimulation. PA has been shown to
modulate mTOR activity by direct binding to its FKBP12-rapamycin binding domain. Additionally, it has been suggested
that exogenous PA activates mTORC1 via extracellular conversion to lysophosphatidic acid and subsequent binding to
endothelial differentiation gene receptors on the cell surface. Recent trials have therefore evaluated the effects of PA
supplementation in resistance-trained individuals on strength and body composition. As research in this field is rapidly
evolving, this review attempts to provide a comprehensive overview of its biosynthesis, pharmacokinetics, mechanisms of
action and effect on strength and body composition in resistance-trained individuals.
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Background
Skeletal muscle mass comprises roughly half of our body
mass and is essential for locomotion, heat production
during periods of cold stress and overall metabolism [1].
Skeletal muscle mass can be increased by mechanical
loading such as a resistance exercise program [2]. The
hypertrophic response to mechanical loading can be
enhanced by employing dietary strategies, such as opti-
mizing protein intake [3], and supplementation strat-
egies, such as creatine monohydrate provision [4]. At
the cellular level, mechanical loading, protein intake,
and several sports supplements have been found to regu-
late mechanistic target of rapamycin complex 1
(mTORC1) activity [5]. mTORC1 is a protein complex
consisting out of the three core subunits mTOR, Raptor
and mLST8 [6]. mTOR forms the catalytic center of the
complex and functions as a serine/threonine protein kin-
ase belonging to the phosphatidylinositol-3 kinase
(PI3K)-related kinase (PIKK) superfamily [7]. mTORC1
acts as a signal integrator of various environmental cues
and controls protein synthesis, specifically the process of
protein translation initiation, through its downstream ef-
fectors p70 ribosomal protein S6 kinase 1 (p70S6K1)
and eukaryotic translation initiation factor 4E-binding
protein 1 (4E-BP1) [8]. Phosphorylation, and thereby ac-
tivation, of p70S6K1 modulates functions of translation
initiation factors [9] and might also promote ribosome
biogenesis and resultingly increase the translational cap-
acity of the cell [10]. Its other substrate, 4E-BP1, inhibits
mRNA translation initiation by preventing formation of
the eIF4F complex which facilitates recruitment of the
small (40S) ribosomal subunit to the 5′ end of mRNA
[11]. Phosphorylation of 4E-BP1 by mTORC1 results in
its dissociation of the mRNA strand and therefore
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relieves the inhibition it poses on formation of the eIF4F
complex.
Several inputs which regulate mTORC1 have been
identified, such as growth factors (e.g. insulin [12] and
insulin-like growth factor 1 [IGF-I] [13]), amino acids
[14], mechanical stimuli [15] and energy status [16].
Interestingly, regulation of mTORC1 activity by mechanical
stimuli has been suggested to be mediated by phosphatidic
acid (PA) formation [17]. Moreover, the branched-chain
amino acid leucine, an important regulator of mTORC1 ac-
tivity, has also been found to activate phospholipase D1
(PLD1) and induce its subcellular translocation to the lyso-
some (the site of mTORC1 activity) [18]. PLD1 hydrolyses
phosphatidylcholine (PC) producing PA.
PA is a phospholipid consisting out of a glycerol back-
bone with two fatty acids and one phosphate group
attached to it. The two fatty acids are attached to two
neighboring C-atoms at position sn-1 and sn-2, with the
phosphate group attached to the C-atom at position
sn-3. The fatty acid at the sn-1 position is often a sat-
urated one, whereas the fatty acid at the sn-2 position is
often unsaturated [19]. The fatty acid composition of PA
appears critical in its ability to activate mTORC1. Specific-
ally, research has shown that PA species containing one or
two unsaturated fatty acid chains activate mTORC1 both
in human embryonic kidney (HEK) 293 cells, as well as in
vitro, whereas saturated PA species have no significant ef-
fect [20]. Furthermore, in a comparison between soy-
derived PA and egg-derived PA, soy-derived PA was more
effective in increasing mTORC1 signaling, as derived from
p70S6K1 phosphorylation on Thr389, in C2C12 myoblasts
[21]. It is appealing to speculate that the higher unsatur-
ated fatty acid content of soy-derived PA compared to
egg-derived PA underlies this difference.
Given the apparent role of PA in mTORC1 regulation,
researchers soon evaluated its supplementation in
resistance-trained men in order to assess its effect on
strength, muscle thickness and lean tissue accruement in a
pilot study [22]. Following this pilot study, several other
human trials have also evaluated the effect of phosphatidic
acid supplementation in athletes [21, 23–25]. As research
in this field is rapidly evolving, this review attempts to
provide a comprehensive overview of its biosynthesis,
pharmacokinetics, mechanisms of action and effect on
strength and body composition in resistance-trained
individuals.
Biosynthesis and metabolism
PA holds a central role in membrane glycerophospholipid
and triacylglycerol synthesis as their biosynthetic precur-
sor [26] and can be generated by three major mechanisms
[27] (see Fig. 1). One of these metabolic pathways is able
to generate PA de novo. This de novo pathway originates
from glycerol-3-phosphate (G3P). G3P can be formed
from one of the intermediate products of glycolysis. During
glycolysis sugar is converted into fructose-1, 6-biphosphate
and subsequently cleaved into two three-carbon units,
namely dihydroxyacetone phosphate (DHAP) and
glyceraldehyde-3-phosphate (not to be confused with
G3P). The generated DHAP can then be reduced into G3P,
a reaction catalyzed by glycerol-3-phosphate dehydrogen-
ase (GDPH). GDPH is an integral membrane protein of
the endoplasmic reticulum (ER) and outer mitochondrial
membrane and its expression in the outer mitochondrial
membrane is induced by insulin signaling [28]. Follow-
ing the production of G3P, two acylation reactions take
place to generate PA. The first acylation reaction producing
lysophosphatidic acid (LPA) is catalyzed by glycerol-3-
phosphate acyltransferase (GPAT) and the second acylation,
resulting in PA, is catalyzed by lysophosphatidic acid acyl-
transferase (LPAAT). Both dietary fatty acids and de novo
synthesized palmitic acid can contribute the required acyl-
CoA groups. Moreover, overexpression of LPAAT-θ has
been found to induce mTOR-dependent p70S6K1 and 4E-
BP1 phosphorylation and is expressed in skeletal muscle
tissue [29]. Several other isoforms also appear to be
expressed in murine skeletal muscle [30], although their
role in mTOR regulation is unclear. Currently, not much is
known about the regulation of LPAAT by growth factors or
nutrients. Finally, it should be noted, that this de novo path-
way has a strong preference for producing PA species with
two saturated fatty acids [31].
In a second pathway, PC is hydrolyzed into PA and
choline. A reaction catalyzed by phospholipase D (PLD).
PLD has been hypothesized to play a crucial role in the
mechanical activation of mTOR signaling and the iso-
zymes PLD1 and PLD2 can be found in the z-band of
skeletal muscle [32]. Moreover, pharmacological inhib-
ition of PLD with the primary alcohol 1-butanol pre-
vents both an increase in PA as well as mTOR signaling
[32]. However, recent research showed that activation of
PLD was not required for the mechanically induced in-
crease in mTOR signaling [33]. This appears to contra-
dict previous experiments which showed that PLD was
crucial in mediating this increase. However, these experi-
ments were mainly based on pharmacological inhibition
of PLD by 1-butanol. Concerns were raised that some of
1-butanol’s biological effects are not specific to inhibit-
ing PLD activity [34]. Moreover, earlier findings indi-
cated that mechanically induced PLD activity poorly
correlated with the cellular increase of PA [32]. PLD1 has
also recently been implicated in mTORC1 activation by
the branched-chain amino acid leucine [18], an important
regulator of mTORC1 activity [35]. It was found that, in a
leucine-dependent manner, leucine tRNA synthetase inter-
acts with the lipid kinase Vps34. In turn, Vps34 produces
phosphatidylinositol-3-phosphate (PI(3)P) which interacts
with the PX domain of PLD1. This interaction
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translocates PLD1 to the lysosome, the site of
mTORC1 activity, and produces PA. Additionally,
some growth factors, such as insulin and insulin-like
growth factor 1, have also been demonstrated to
regulate PLD activity [36].
A third pathway which generates PA utilizes diacylglyc-
erol (DAG) as its substrate. DAG can emanate from stored
fat as triacylglycerol, as well as the glycerophospholipid
phosphatidylinositol (PI). In order to produce DAG from
triacylglycerol, one of the outer acyl-CoA groups is deacy-
lated by a lipase. Conversely, DAG synthesis from PI
requires removal of the inositol group. The enzyme
phospholipase C (PLC) catalyzes this reaction. DAG is
phosphorylated by DAG kinase (DGK) or PRK-like ER
kinase (PERK) into PA [37]. PERK is found in the
endoplasmic reticulum (ER) membrane. Notably, it ex-
hibits phosphoinositide-3 kinase (PI3K)-dependent kinase
activity [37]. This might provide an interesting link between
PA-mTORC1 signaling and the canonical activation of
mTORC1 by growth factors mediated by PI3K/Akt signal-
ing. Nevertheless, this link currently remains largely unex-
plored. A larger body of literature has examined the role of
DGKs. DGKs belong to a large family of intracellular lipid
kinases [38]. Several isoforms have been identified and the
ζ-isoform has received special attention as overexpression
of the isoform in serum-deprived HEK293 cells lead to an
increase in p70S6K1 phosphorylation in an mTOR-
dependent manner [39]. Moreover, DGKζ has recently been
shown to be necessary for a mechanically induced increase
in PA-mTOR signaling [33]. Overexpression of DGKζ was
found to be sufficient to induce muscle fiber hypertrophy
through an mTOR-dependent mechanism.
In summary, current evidence indicates that PA syn-
thesized by DGKζ, but not PLD, is responsible for the
mechanical activation of mTOR signaling and hyper-
trophy. However, PLD has been implicated in mTORC1
activation by leucine and PLD activity has been demon-
strated to be regulated by growth factors such as insulin
and IGF-1. The first step in the de novo pathway originat-
ing from GDP and catalyzed by GPAT, is induced by insu-
lin. However, the regulation of the second and final step
by growth factors and nutrients remains unexplored.
The metabolism of PA follows two important paths in
the de novo synthesis of glycerophospholipids and triac-
ylglycerol. One path leads to the storage of energy in
adipose tissue: triacylglycerol biosynthesis. A PA phos-
phatase hydrolyzes the bond with the phosphate group
to yield DAG and Pi [40]. The formed DAG can then be
esterified with a third fatty acyl-CoA group to produce
triacylglycerol for fat storage. The produced DAG can
also be diverted towards the Kennedy pathway yielding
the two glycerophospholipids phosphatidylethanolamine
(PE) and PC [41]. Both form important constituents of
mammalian cell membranes, with PC being the most
abundant and PE being the second most abundant
phospholipid [42].
A second pathway is directly aimed at glycerophospholi-
pid synthesis. PA is activated by cytidine diphosphate
(CDP) forming CDP-diacylglycerol and is catalyzed by
CDP-diacylglycerol synthase [26]. This step is quite analo-
gous to the activation of glucose by uridine diphophate
(UDP) as seen in glycogen synthesis. Following the acti-
vation of PA by CDP, it can then be converted to PI,
phosphatidylglycerol (PG) and cardiolipin (CL). PI is a pre-
cursor of phosphoinositides, such as phosphatidylinositol
(3, 4, 5)-trisphosphate (PIP3), which play an important role
in intracellular signaling, vesicular trafficking and cytoskel-
eton dynamics [43]. PG and CL play an important role in
Fig. 1 Metabolism of PA. PA can be synthesized from various sources. A de novo pathway originates from G3P. G3P is acetylated twice, requiring fatty-
acyl-CoA for its acetylation. First it is acetylated by GPAT and then by LPAAT. A second pathway uses PC. PC is hydrolyzed by PLD to produce PA. Finally,
PA can be produced by the phosphorylation of DAG by DAG kinase (DGK). DAG is derived from triacylglycerols and phosphatidylinositol. PA
phosphatase (PA P’tase) is responsible for dephosphorylation of PA to DAG. Various CDP-diacylglycerol synthases produce CDP-diacylglycerol
from PA. Figure based on [27]
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proper functioning of the mitochondria [44] and are also
involved in molecular signaling of numerous other cellular
processes [45].
Additionally, the acyl group at position sn-2 can be
hydrolyzed by phospholipase A2 (PLA2) producing LPA.
Absorption
Several foodstuffs contain PA, albeit in extremely small
quantities. Using a thin-layer-chromatography-imaging
technique, Tanaka et al. quantified the PA content in 38
foodstuffs and 3 herbs [46]. The largest amounts of PA
were found in vegetables belonging to Brassicaceae, such
as cabbage (Brassica oleracea) which contained 700
nmol/g (approximately 0.5 mg/g). Human trials have
employed PA supplements with doses varying from 250
mg [24] to 750 mg [21–23, 25] in resistance-trained
men. As such, the amount of PA found in the diet is
negligible to what is employed for supplementation
purposes in resistance-trained individuals.
When administered orally, PA is metabolized to lyso-
phospholipids and glycerol-3-phosphate in the intestinal
lumen by several pancreatic phospholipases [19]. These
pancreatic phospholipases hydrolyze the ester bonds at
position sn-1 or sn-2. There appears to be a specificity
for the bond at sn-2, in particular by PLA2 [47]. Subse-
quently, these products (mainly lysophospholipids with a
fatty acid at position sn-1) are then absorbed by the
intestinal mucosa. The lysophospholipids can then be
re-esterified with a fatty acid in the enterocytes, thus
producing PA again. Further esterification to form triac-
ylglycerol can also take place. The formed phospholipids
will be incorporated into the outer layer of chylomi-
crons. Following exocytosis, the chylomicrons will be
transported through the lymphatic system in order to ar-
rive in the blood circulation. Due to its transport via the
lymphatic system, rather than through the liver via the
portal vein, it will take longer to reach the circulation
than most other sports supplements. A poster presenta-
tion reports that, after a single dose of 1.5 g soy-derived
PA in one subject, peak plasma concentrations of PA are
reached at 3 h after oral ingestion and were still elevated
after 7 h [48]. The peak PA concentration was 32%
higher than the baseline value of 2.66 nmol/ml. The
baseline plasma concentration of LPA was 0.11 nmol/ml
and it showed a bimodal absorption kinetic with peaks
after 1 h (+500%) and 3 h (+264%), after almost drop-
ping back to baseline after 2 h. Nevertheless, data in a
single subject is of very limited value. Future research
investigating PA pharmacokinetics in multiple subjects
with varying doses is warranted.
It is currently unclear how much PA eventually reaches
skeletal muscle tissue and is absorbed by the muscle cells
or is incorporated in their membranes. However, when
added to cell culture media, PA is rapidly incorporated
into cellular membranes [49]. Nevertheless, for its action
on mTORC1 activity it might not be required for PA to
reach skeletal muscle cells intact. Some evidence suggests
that exogenous PA must be metabolized extracellularly to
LPA in order to activate mTORC1 [50].
Mechanisms of action
In 2001, Feng et al. demonstrated a key role of PA in
mTORC1 regulation [49]. In their experiment, an extra-
cellular concentration of 100 μM PA stimulated p70S6K1
activity and 4E-BP1 phosphorylation in HEK263 cells.
Addition of the mTOR inhibitor rapamycin abolished this
effect, thus indicating that the stimulation of p70S6K1 ac-
tivity and 4E-BP1 phosphorylation by PA was mTOR
dependent. Still it is unknown if similar extracellular PA
concentrations are reached in humans after oral ingestion
of PA, although the previously discussed study demon-
strated a plasma concentration of only ~3 μM after inges-
tion of 1.5 g PA. Additionally, serum-starved HEK263
cells stimulated with 10% serum showed an increase in
cellular PA, p70S6K1 activity and 4E-BP1 phosphoryl-
ation. Treatment with 0.3% 1-butanol inhibited p70S6K1
activity, 4E-BP1 phosphorylation and the increase in PA.
These observations lead to the hypothesis that mitogenic
stimulation of mTOR is mediated by PA. Later evidence
revealed that PA can modulate mTOR activity by direct
binding to its FKBP12-rapamycin binding (FRB) domain
[51]. The FRB domain lends its name to the potent
pharmacological mTOR inhibitor rapamycin which tightly
binds the site in complex with FKBP12 and thereby
inhibits mTOR catalytic activity. A later experiment by
Hornberger et al. demonstrated that mechanical stimula-
tion, which increases the cellular PA concentration,
increased the half maximal inhibitory concentration (IC50)
of rapamycin compared to control. This provided further
evidence supporting the hypothesis that competition takes
place between the FKBP12-rapamycin complex and PA
for binding to the FRB domain [32]. However, since rapa-
mycin must be administered exogenously, this does not
explain an effect of PA on mTORC1 activity in the
absence of rapamycin. An endogenous inhibitor, FKBP38,
also binding to the FRB domain, was later identified [52].
Importantly, Yoon et al. demonstrated that FKBP38 is dis-
placed by PA and thereby alleviates the inhibition it
imposes on mTORC1 activity [53]. Additionally, they also
determined that PA was able to allosterically activate
mTORC1, since PA was still able to stimulate mTORC1
signaling after FKBP38 knock-down. Therefore the
authors proposed that the action for PA activation of
mTORC1 was twofold by: i) displacing the endogenous
inhibitor FKBP38 from the FRB domain, and ii) allosteri-
cally stimulating catalytic activity of the complex.
In contrast, it has been suggested that exogenous PA
does not activate mTORC1 through internalization and
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subsequent direct interaction with mTOR. Instead, PA
would require extracellular conversion to LPA by phos-
pholipases which would then bind and activate endothe-
lial differentiation gene (EDG-2) receptors on the cell
surface [50]. Activation of this G-protein coupled recep-
tor would then activate the MEK-ERK pathway. Activa-
tion of this pathway can then stimulate mTORC1
activation by inhibiting the tuberous sclerosis complex
[54] and Raptor [55]. In addition to activation of the
MEK-ARK pathway, the authors also propose that acti-
vation of EDG-2 leads to a rise in intracellular PA due to
an increase in PLD activity.
In order to test the hypothesis that a mechanically-
induced increase in PA activates mTORC1, You et al.
employed the MEK/ERK inhibitor U0126 in an ex-vivo
model [56]. Intermittent passive stretch was applied to
mouse extensor digitorum longus (EDL) muscles for
mechanical stimulation. This resulted in an increase in
ERK phosphorylation (Thr202/Tyr204) which indeed
was effectively blocked by addition of U0126, thus valid-
ating its usage as an inhibitor in their experimental
model. However, while U0126 decreased the basal levels
of p70S6K1 phosphorylation (Thr389 and Thr421/
Ser424), it did not block the mechanically-induced
increase in phosphorylation of p70S6K1 on these resi-
dues. Similarly, mechanical stimulation increased 4E-
BP1 phosphorylation (Ser64) both with and without
U0126. These results suggest that ERK is not necessary
for mechanically-induced mTOR signaling. Nevertheless,
U0126 did attenuate the increase in phosphorylation of
both p70S6K1 and 4E-BP1 in response to mechanical
stimuli. Additionally, the authors incubated C2C12 myo-
blasts with exogenous PA in the presence or absence of
U0126. This lead to similar results as found with the
ex-vivo model. U0126 did not block the increase in
phosphorylation of either 4E-BP1 and p70S6K1, but
nevertheless attenuated it. Based on the assumption
that PA is required for a mechanically-induced activa-
tion of mTOR, the observation that PA increased in the
ex-vivo model and the similarity in results with the in
vitro experiment, the authors suggest that mechanical
stimulation induces mTOR signaling via an ERK-
independent mechanism that potentially involves PA.
In addition, PA might promote an increase in muscle
mass by affecting the expression of various factors in-
volved in the ubiquitin-proteasome pathway. The FoxO
family of transcription factors play an important role in
muscle protein breakdown by modulating the activity of
the ubiquitin-proteasome and autophagy-lysosomal pro-
teolytic pathways [57]. Among the factors regulated by
FoxO are the two E3 ligases muscle atrophy F-box
(MAFbx, also known as atrogin-1) and muscle ring fin-
ger 1 (MuRF1). Both of which are considered important
regulators of muscle atrophy [58, 59]. Overexpressing
the PA-generating enzyme PLD1 in fully differentiated L6
myotubes decreased FoxO3, MAFbx and MuRF1 mRNA
expression [60]. Additionally, incubation of the myotubes
with 100 μM PA also inhibited the dexamethasone-
induced increase in mRNA expression of these factors.
Importantly, addition of exogenous PA was able to attenu-
ate both dexamethasone and tumor necrosis factor alpha
(TNFα)-induced atrophy of the myotubes. A possible
mechanism for this action of PA might be via mTORC2.
mTORC2 differs structurally from mTORC1 in that it not
contains Raptor but Rictor [61]. Its role in muscle hyper-
trophy appears less prominent than that of mTORC1.
However, mTORC2 phosphorylates, and thereby acti-
vates, Akt on a serine residue. Full Akt kinase activity is
achieved when both its threonine (phosphorylated by 3-
phosphoinositide dependent protein kinase [PDK1])
and serine residue are phosphorylated [62, 63]. Acti-
vated Akt in turn phosphorylates various substrates,
among which are FoxO proteins [64]. Consequently,
FoxO regulates expression of MAFbx and MuRF1.
Effect on strength and body composition in
resistance-trained individuals
Several trials have recently evaluated the ergogenic
effects of PA in resistance-trained men. In 2012, Hoff-
man et al. ran a pilot study with sixteen resistance-
trained men [22]. The men were randomly assigned to
either ingest 750 mg PA daily or a placebo for 8 weeks.
During these 8 weeks the men were instructed to follow
a 4-day per week split-routine unsupervised resistance
training program. Body composition (body weight, lean
body mass [LBM] and body fat), strength (1-RM bench
press and 1-RM squat) and ultrasonography measure-
ments (vastus lateralis thickness and pennation angle)
were made before and after the supplementation period.
No significant interaction between the groups was
found, although a trend (p = 0.065) towards a significant
interaction was found for LBM change. The authors
continued to statistically evaluate the results with
magnitude-based inference (MBI). This indicated a likely
benefit from PA for increasing 1-RM squat and a very
likely benefit for increasing LBM. However, MBI results
should be viewed with caution and usage of the statis-
tical method is discouraged by some authors [65]. It
should also be noted that there was essentially no
change in LBM (+0.1 kg) in the placebo group, which
might imply that the training stimulus was inadequate
for muscle hypertrophy. Due to the small sample size,
the study might have suffered from a type II error.
Following this pilot study, Joy et al. employed a simi-
lar research design in resistance-trained men (n = 28)
[21]. The PA dosage was equal to that used by Hoffman
et al. and participants followed a 3-day per week undu-
lating resistance training program during an 8-week
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supplementation period. In addition, the time of PA-
intake was controlled for in this study. PA was taken 30
min pre-workout (450 mg) and immediately post-
workout (300 mg) on training days. On rest days, PA
was taken with breakfast (450 mg) and dinner (300
mg). The PA group gained a significantly greater
amount of LBM (+2.4 kg) over the 8-week period com-
pared to the placebo group (+1.2 kg). No significant dif-
ferences were observed between groups for 1-RM leg
press, 1-RM bench press and fat mass change, although
the latter showed a trend towards significance (p =
0.068). Additionally, ultrasonography revealed a signifi-
cant CSA increase of the rectus femoris in the PA
group compared to the placebo group.
Escalante et al. randomly assigned eighteen healthy
strength-trained males to either a group consuming a
PA-containing multi-ingredient supplement or a placebo
for 8 weeks in conjunction with a 3-day per week undu-
lating resistance training program [23]. The multi-
ingredient supplement also contains other ingredients
which can affect results, including leucine, β-hydroxy β-
methylbutyrate (HMB) and vitamin D3. It is therefore
completely uncertain to what extent, if any, PA affected
the results of this study. However, in line with the results
of Hoffman et al. and Joy et al., a significant increase in
LBM change (as assessed by dual-energy X-ray absorpti-
ometry [DXA]) was measured in the PA group com-
pared to the placebo group. Additionally, men in the PA
group significantly increased their 1-RM bench press
and 1-RM leg press compared to the placebo group. Al-
though the PA group tended to lose more fat mass than
the placebo group, the result was not significant. Thigh
muscle mass (as also assessed by DXA), vertical jump,
push-ups to failure, pro-agility shuttle time and peak
power output were also measured but did not show any
significant differences between groups.
Recently, a study by Andre et al. also investigated the
efficacy of lower dosages of PA (250 mg and 375
mg daily) combined with resistance training [24]. A total
of 28 men was randomized to a PA group consuming
250 mg daily (PA250, n = 9), 375 mg daily (PA375, n = 9)
or a placebo (PLC, n = 10). Similar to previous research,
participants were resistance-trained and body compos-
ition, muscle size and lower-body muscle strength were
determined before and after the supplementation period.
However, no test for upper-body muscle strength was
performed. Slightly deviating from previous research was
timing of supplement intake. Whereas Joy et al. and
Hoffman et al. provided PA 30 m before and directly
after training, participants in this study took the supple-
ment 60 min before training. ANOVA revealed no sig-
nificant group × time interactions. Like Hoffman et al.,
the authors continued statistical analysis with MBI. Ap-
plication of MBI showed a likely positive effect of PA on
LBM and CSA of the rectus femoris compared to pla-
cebo, and a very likely positive effect on the 1-RM leg
press in PA250 compared to PLC. PA375 also showed a
likely positive effect on CSA of the rectus femoris, 1-RM
leg press and a possible positive effect on LBM com-
pared to PLC. However, some of the data reported in the
study appear internally inconsistent, since the mean
LBM change in both PA250 (+0.5 kg) and PA375 (+1.3
kg) was smaller than in PLC (+1.6 kg). This appears in
conflict with the reported MBI results. Nevertheless, the
lack of any significant effect as indicated by ANOVA
compared to previous research might be explained by
subtle differences between studies. One pronounced dif-
ference is the used dosage. Whereas the previous studies
provided 750 mg PA daily to the participants, the re-
search by Andre et al. only provided half (PA375) or one
third of this (PA250).
Given the equivocal results in literature, Gonzalez et
al. examined the efficacy of 750 mg of PA on muscle
thickness and strength gains in resistance-trained men
using a study design very similar to previous research
[25]. Unfortunately, total body composition was not
assessed by the authors. A total of fifteen resistance-
trained men participated in the study and were
instructed to follow an 8-week supervised resistance-
training program with training sessions 3 days per week.
Half the PA dose was taken 30 min prior to and the
other half was taken directly after resistance exercise.
On rest days, half the PA dose was taken with breakfast
and the other half was taken with dinner. Muscle thick-
ness of the rectus femoris, vastus lateralis, biceps brachii
and triceps brachii muscles were measured via ultrason-
ography and 1-RM of squat, deadlift and bench press
were performed as strength measures. Although all par-
ticipants made improvements in each measure of muscle
thickness and strength, no significant differences be-
tween the PA and placebo group were found.
Excluding the study by Escalante et al. because of sup-
plementing PA in conjunction with other active ingredi-
ents, only the study by Joy et al. demonstrated significant
improvements in lower body strength and LBM compared
to placebo. Andre et al. and Hoffman et al. only found
likely improvements when applying magnitude-based in-
ference. Finally, the recent trial by Gonzalez et al. found
no improvement at all in muscle thickness or in strength.
It is uncertain what resulted in these differing results as
there do not appear to be clear differences between
studies, with the exception of the lower dosage used by
Andre et al. (250 mg and 375 mg daily) in comparison
to all other trials (750 mg daily). Nevertheless, small
differences exist and Gonzalez et al. enumerated the
following potential discrepancies: exercise supervision,
resistance-training program design, dietary adherence, ex-
ercise selection for assessing maximal strength, timing of
Bond Nutrition & Metabolism  (2017) 14:12 Page 6 of 9
supplement ingestion, methods of assessing changes in
muscle architecture and body composition and training
status of study participants. It should also be noted that
due to the small sample sizes used in these trials, a small
effect might be easily missed.
Conclusions
A considerable amount of research at the molecular level
implicates that PA is closely involved in regulation of the
mTORC1 pathway. The mTORC1 pathway is intimately
involved in regulation of skeletal muscle size through
regulation of muscle protein synthesis. Additionally, PA
might affect muscle protein breakdown as well through
regulation of FoxO, MuRF1 and MAFbx. This effect might
be mediated by influencing mTORC2 activity. It would
therefore be interesting to see the effect of PA supplemen-
tation on muscle mass in catabolic conditions such as
cachexia or sarcopenia. However, research into the effects
of PA on muscle protein breakdown is currently very
limited and its practical relevance remains unknown.
A small number of studies carried out with resistance-
trained men suggest that PA supplementation might be
a useful dietary strategy to increase muscle mass and
possibly strength in this population, although only one
study has found a statistical significant effect on these
parameters. This might be due to differences between
studies or because of a small effect which would require
larger sample sizes to consistently reach statistical
significant results.
Although PA is a phospholipid present in the mem-
branes of cells, its presence in the diet is negligible and
supplementation would be required for any potential
ergogenic benefits. An appropriate dosage based on the
current state of research would be 750 mg supplemented
daily. A lower dosage appears to be ineffective at in-
creasing LBM or strength. An optimal time of ingestion
has not yet been established. It therefore seems appro-
priate to recommend ingestion times in line with studies
which have demonstrated benefits of the compound in
athletes. Joy et al. [21] and Escalante et al. [23] showed
positive effects when 450 mg PA was taken 30 m before
training and 300 mg directly after. On rest days, 450 mg
PA was taken with breakfast and 300 mg with dinner.
Given that PA is hydrolyzed before absorption by the in-
testinal mucosa, after which it is re-esterified with fatty
acids in the enterocytes, the fatty acid composition of
the meal with which PA is taken might influence its effi-
cacy. However, no research has evaluated this to date
and it would be interesting to see if and to what extent
the fatty acid composition of simultaneous meal inges-
tion would influence the fatty acid composition of PA
reaching the bloodstream and its pharmacokinetics.
Given that some research suggests that PA species con-
taining one or two unsaturated fatty acid chains are
more effective than saturated PA species in activating
mTORC1, this would be of high interest. Finally, it
should be noted that research investigating the safety of
PA supplementation is severely lacking. Although no
subjects in the discussed human trials reported side-
effects, long-term data is lacking as well as more detailed
safety data. Future studies aimed at collecting safety data
should be conducted to fill this gap in the literature.
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